Amphista is identifying and advancing novel approaches in targeted protein degradation (TPD) to develop a new generation of innovative therapies with significantly improved efficacy.
The company’s proprietary Eclipsys™ Drug Development platform is rapidly expanding the therapeutic applications of this transformational modality.
Careers
Amphista offers an exciting and fast-moving working environment that fosters opportunity. Come and join our team and help us make a positive difference for patients.
Latest News
- Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics 4 May 2022
- Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics 4 May 2022
